Abstract Body

Direct-acting antivirals (DAA) lead to high rates of Hepatitis C (HCV) cure. Bolstered by the results of DAA treatment, the World health Organization has called for HCV elimination by 2030. Given this task, HCV mirco-elimination has gained burgeoning support, and people with HIV have been identified as a population in which micro-elimination may be feasible. Here, we describe the HCV care continuum and progress towards HCV elimination in an urban HIV clinic population.

We examined progress through the HCV care continuum among patients infected with HIV/HCV receiving HIV care in an HIV clinic at Johns Hopkins Hospital in Baltimore, MD. Individuals were eligible for inclusion in the study if they had HIV visits in at least 2 consecutive years between January 1, 2013 and December 31, 2016 and had a detectable HCV RNA. Patients were followed through March 31, 2018 for referral to HCV care, HCV treatment initiation and cure (undetectable HCV RNA 12 weeks post-treatment). Multivariable logistic regression was used to identify demographic and clinical characteristics associated with HCV treatment initiation.

Among 594 HIV/HCV coinfected individuals, the median age was 57 years (interquartile range (IQR) 52-61), 89% were black, 67% male, 51% had a psychiatric history, 73% had a history of injection drug use and 34% reported heroin and/or cocaine use in the preceding 3 months. The median CD4 count was 462 (IQR 295-673) cells/mm3; most (79%) were on antiretroviral therapy (ART), had HIV RNA <400 copies/ml (75%) and were infected with HCV genotype 1 (96%). The majority were insured by Medicaid (51%). Assessing the HCV care continuum in these 594 coinfected patients, 547 (92%) were referred for care, 517 (87%) were evaluated for treatment, 457 (77%) were prescribed treatment, 426 (72%) initiated treatment, and 381 (64%) had achieved HCV cure as of March 31, 2018. In multivariable analyses, >F2 liver fibrosis (odds ratio [OR], 3.12, 95% confidence interval [CI], 1.40-6.96) was positively associated with HCV treatment initiation. Conversely, being on ART with an HIV RNA >400 (OR, 0.22 (95% CI 0.13-0.35) and ≥50% missed HIV care visits (OR, 0.33; 95% CI, 0.17-0.62 compared to no missed visits) were independently negatively associated with HCV treatment initiation. Recent illicit drug use was not associated with treatment initiation.

Oral DAAs alone are not sufficient to achieve HCV micro-elimination. Improved engagement in HIV care is critical to this goal.